VistaGen Therapeutics (NASDAQ:VTGN) Posts Quarterly Earnings Results

Key Points

• VistaGen Therapeutics reported a quarterly EPS of ($0.47), meeting the consensus estimate, with revenues of $0.24 million exceeding expectations.
• The company's stock has seen an 8.8% increase to $2.97, with a market capitalization of $88.68 million and a PE ratio of -1.67.
• Institutional investors hold 78.39% of VistaGen's stock, indicating strong interest, with a recent stake bought by a hedge fund valued at approximately $25,000.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.47) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.47), Zacks reports. The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.22 million. VistaGen Therapeutics had a negative return on equity of 74.06% and a negative net margin of 6,777.08%.

VistaGen Therapeutics Price Performance

Shares of VistaGen Therapeutics stock traded up $0.07 on Wednesday, reaching $2.93. The company had a trading volume of 246,650 shares, compared to its average volume of 215,815. The firm has a market cap of $89.74 million, a price-to-earnings ratio of -1.64 and a beta of 0.40. The firm's 50-day moving average price is $2.46 and its two-hundred day moving average price is $2.50. VistaGen Therapeutics has a 1 year low of $1.90 and a 1 year high of $3.79.

Wall Street Analysts Forecast Growth

Separately, William Blair reaffirmed an "outperform" rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 18th.

Hedge Funds Weigh In On VistaGen Therapeutics

An institutional investor recently raised its position in VistaGen Therapeutics stock. Bank of America Corp DE boosted its holdings in shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 1,068.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,141 shares of the company's stock after acquiring an additional 19,331 shares during the quarter. Bank of America Corp DE owned 0.08% of VistaGen Therapeutics worth $62,000 as of its most recent SEC filing. 78.39% of the stock is owned by institutional investors and hedge funds.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.